In in a bid to create a vaccine against the deadly HINI virus, scientists at the St Petersburg Flu Research Institute have requested the US Centre for Disease Control and Prevention (CDC, Atlanta),to share with them details of the highly pathogenic A/H1N1/ virus strain.
"After we have received biological material from US, we will study the genetic structure of the mutant virus. Based on the data we are going to obtain, we will create a sufficiently effective vaccine," Institutes academic secretary Tamara Lobova told Itar-Tass.
"It may take three to five months to complete this process from development to production of the anti-viral vaccine," Lobova added.
On the other hand All-Russia Research Institute of Veterinary Virology and Microbiology has already begun work to create a vaccine for the same.
"We thought about an anti-virus when the so-called avian flu appeared. Our scientists suggested that if pigs were infected with the avian flue, we should expect a new virus to emerge," institute's chief consultant Igor Bakumov said.
However the Siberian research and production company Vektor-best, one of the biggest developers of human disease diagnostic systems, has no plans to create a test for virus
"It will take more than a year to develop a test, and another year, as a minimum, will be needed for its registration. During this the type A (H1N1) flu virus will most likely mutate because the flu germ is genetically very mutable," company Deputy Director-General Yuri Gusev said.
You’ve reached your limit of 5 free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app